English
In recent years, cell factories have emerged as crucial production tools in the pharmaceutical industry, characterized by their multi-layer structure, polystyrene material, and flexible specifications. Their application in industrial-scale production, particularly in vaccine preparation, has demonstrated their exceptional role. Notably, successful cases like the production of rotavirus vaccines using bovine kidney cells highlight the critical role of cell factories in vaccine manufacturing.
Rotavirus is a major pathogen causing diarrheal diseases, particularly severe among infants and young children. Vaccine production is crucial for controlling and preventing the spread of rotavirus, addressing a significant public health challenge. Bovine kidney cells, commonly used as host cells, are extensively employed in the preparation of viral vaccines. The multi-layer structure of cell factories allows large-scale cell culture within relatively small spaces. This characteristic significantly enhances the production efficiency of pharmaceutical manufacturers, making large-scale vaccine production feasible.
Through the use of cell factories, bovine kidney cells can be cultivated under optimal growth conditions. This equipment provides superior surface area, ensuring ample nutrition and optimal growth environment for cells. Its flexible specifications enable manufacturers to adjust production according to demand and capacity, thereby meeting vaccine market needs more rapidly.
In conclusion, the application of cell factories in the preparation of rotavirus vaccines using bovine kidney cells represents a significant advancement in the field of biotechnology. It not only improves the efficiency and quality of vaccine production but also contributes greatly to global public health efforts, playing a crucial role in our collective endeavor to build a healthier society.
The FAI climbed 5.9 percent year-on-year in the first 11 months of 2018, quickening from the 5.7-percent growth in Jan-Oct, the National Bureau of Statistics (NBS) said Friday in an online statement.
The key indicator of investment, dubbed a major growth driver, hit the bottom in August and has since started to rebound steadily.
In the face of emerging economic challenges home and abroad, China has stepped up efforts to stabilize investment, in particular rolling out measures to motivate private investors and channel funds into infrastructure.
Friday's data showed private investment, accounting for more than 60 percent of the total FAI, expanded by a brisk 8.7 percent.
NBS spokesperson Mao Shengyong said funds into weak economic links registered rapid increases as investment in environmental protection and agriculture jumped 42 percent and 12.5 percent respectively, much faster than the average.
In breakdown, investment in high-tech and equipment manufacturing remained vigorous with 16.1-percent and 11.6-percent increases respectively in the first 11 months. Infrastructure investment gained 3.7 percent, staying flat. Investment in property development rose 9.7 percent, also unchanged.